Pharvaris (NASDAQ:PHVS) Issues Quarterly Earnings Results

Pharvaris (NASDAQ:PHVS) posted its quarterly earnings results on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, FiscalAI reports.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $1.30 during trading hours on Thursday, hitting $28.15. The company’s stock had a trading volume of 22,634 shares, compared to its average volume of 166,900. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.85. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -8.77 and a beta of -2.58. The business has a 50-day simple moving average of $27.03 and a 200-day simple moving average of $25.36.

Institutional Investors Weigh In On Pharvaris

A number of large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Pharvaris during the fourth quarter valued at approximately $35,000. Barclays PLC bought a new stake in Pharvaris in the fourth quarter valued at $77,000. China Universal Asset Management Co. Ltd. purchased a new position in Pharvaris during the 3rd quarter valued at $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris during the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. raised its holdings in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PHVS. Guggenheim boosted their target price on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Oppenheimer lifted their price target on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, Leerink Partners set a $38.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharvaris has an average rating of “Moderate Buy” and a consensus price target of $41.70.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.